Three were targets for drugs approved for non-CHD indications but which showed a potentially detrimental effect direction on CHD when instrumented through increasing HDL-C concentration (ESR1, ALOX5, and TUBB). This evidence concerns the gene ALOX5 and coronary artery disorder.